Dr. Wen Hwa Lee
is the Director of the Disease Foundations Network at the Structural Genomics Consortium (SGC – www.thesgc.org ) – a global reference for pre-competitive, Open Science drug discovery, creating and openly sharing outputs in the absence of patents.
Based at the University of Oxford, where he is also responsible for the management of SGC’s strategic alliances. Lee is trained in Biology, Molecular and Structural Biology, Protein Crystallography, Computational Biology and Drug Discovery.
Since joining the SGC in 2004, he has been working with multiple institutions and stakeholders to enable the exchange of expertise and establishment of joint research programmes with SGC’s international partners, including charities, academia, industry, pharmaceutical companies and government agencies – creating novel Open Science models for drug discovery.
He also led the establishment a new SGC laboratory in Brazil – the first node of an international effort focused on novel kinases for Drug Discovery and AgroBio. He is now committed to creating new frameworks and partnerships with patient and disease foundations to bridge the basic science to patient-driven efforts, as well as launching and directing an Oxford Martin School programme to quantify the economic impact of open science efforts for development of novel treatments and medicines (http://www.oxfordmartin.ox.ac.uk/research/programmes/affordable-medicines).